Literature DB >> 21158852

YKL-40 in type 2 diabetic patients with different levels of albuminuria.

Johanna-M Brix1, Florian Höllerl, Renate Koppensteiner, Guntram Schernthaner, Gerit-H Schernthaner.   

Abstract

BACKGROUND: Type 2 diabetic patients with albuminuria have an increased risk for vascular complications. Albuminuria is related to endothelial dysfunction and plaque instability. YKL-40 is also associated with both and elevated in nondiabetic vascular patients. We investigated YKL-40 and its association with vascular disease in type 2 diabetic patients with albuminuria.
MATERIAL AND METHODS: Two hundred and four patients with type 2 diabetes were included in a cross-sectional study: One hundred and six normo- (No-A), 64 micro- (Mi-A) and 34 macroalbuminuric (Ma-A) patients that did not differ for age, diabetes duration, HbA1c, body-mass-index, blood pressure, lipids and creatinine. YKL-40 was measured in serum samples and determined by ELISA.
RESULTS: YKL-40 was significantly different in No-A: 87±57 vs. Mi-A 119±68 vs. Ma-A 157±75ng mL(-1) ; P<0·001. Patients with macrovascular disease showed higher YKL-40 than those without: 115±72 vs. 87±49ng mL(-1) , P=0·003. In correlation analysis, YKL-40 was associated with urinary albumin excretion rate (AER), plasma creatinine, creatinine clearance (CC) and age. Two multivariate regression analyses were conducted: in the first one, AER and CC remained associated with YKL-40 and in the second one AER and age.
CONCLUSIONS: This is the first report of a significant elevation of YKL-40 in type 2 diabetic patients with albuminuria. In addition, we observed a significant association with macrovascular disease. Because we detected an association between YKL-40 with renal, micro- and macrovascular disease, this protein could play an important for the increased risk of type 2 diabetic patients with albuminuria for the development of cardiovascular disease.
© 2010 The Authors. European Journal of Clinical Investigation © 2010 Stichting European Society for Clinical Investigation Journal Foundation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21158852     DOI: 10.1111/j.1365-2362.2010.02446.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  8 in total

1.  Comparative effects of metformin and pioglitazone on YKL-40 in type 2 diabetes: a randomized clinical trial.

Authors:  A Esteghamati; S Rezvani; E Khajeh; M Ebadi; M Nakhjavani; S Noshad
Journal:  J Endocrinol Invest       Date:  2014-08-20       Impact factor: 4.256

2.  YKL-40 A Sensitive Biomarker for Early Androgenetic Alopecia and Early Hidden Metabolic Syndrome.

Authors:  Doaa M Elhabak; Walid Abdel Abdel Halim
Journal:  Int J Trichology       Date:  2020-05-05

3.  YKL-40 levels are independently associated with albuminuria in type 2 diabetes.

Authors:  Anne K Røndbjerg; Emina Omerovic; Henrik Vestergaard
Journal:  Cardiovasc Diabetol       Date:  2011-06-22       Impact factor: 9.951

4.  Associations of the Inflammatory Marker YKL-40 with Measures of Obesity and Dyslipidaemia in Individuals at High Risk of Type 2 Diabetes.

Authors:  Stine B Thomsen; Anette P Gjesing; Camilla N Rathcke; Claus T Ekstrøm; Hans Eiberg; Torben Hansen; Oluf Pedersen; Henrik Vestergaard
Journal:  PLoS One       Date:  2015-07-21       Impact factor: 3.240

5.  YKL-40 and its complex association with metabolic syndrome, obesity, and cardiovascular disease.

Authors:  Gerit Holger Schernthaner; Clemens Höbaus; Johanna Brix
Journal:  Anatol J Cardiol       Date:  2016-12       Impact factor: 1.596

6.  Urinary cell cycle arrest biomarkers and chitinase 3-like protein 1 (CHI3L1) to detect acute kidney injury in the critically ill: a post hoc laboratory analysis on the FINNAKI cohort.

Authors:  Eric A Hoste; Suvi T Vaara; Jorien De Loor; Mikko Haapio; Lieve Nuytinck; Kristel Demeyere; Ville Pettilä; Evelyne Meyer
Journal:  Crit Care       Date:  2020-04-10       Impact factor: 9.097

7.  Increased levels of YKL-40 in patients with diabetes mellitus: a systematic review and meta-analysis.

Authors:  Wanwan Luo; Lingmin Zhang; Lingling Sheng; Zhencheng Zhang; Zaixing Yang
Journal:  Diabetol Metab Syndr       Date:  2021-01-15       Impact factor: 3.320

8.  The Association between genetic variations of CHI3L1, levels of the encoded glycoprotein YKL-40 and the lipid profile in a Danish population.

Authors:  Stine Brinkløv Thomsen; Camilla Noelle Rathcke; Tea Skaaby; Allan Linneberg; Henrik Vestergaard
Journal:  PLoS One       Date:  2012-10-05       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.